Overview
Diffuse high-grade B-cell lymphoma (DHGB-DL) represents a subset of aggressive non-Hodgkin lymphomas characterized by rapid proliferation and dissemination. These lymphomas are clinically significant due to their poor prognosis and the need for prompt and intensive therapeutic interventions. Despite advancements in treatment modalities, including intensive chemotherapy regimens and targeted therapies, the overall survival rates remain challenging, emphasizing the importance of comprehensive patient care that includes not only medical management but also supportive measures such as advance care planning (ACP). The evidence highlights critical gaps in patient engagement with ACP, underscoring the necessity for enhanced communication strategies between healthcare providers and patients to improve outcomes and quality of life.
Diagnosis
Diagnosis of DHGB-DL typically involves a combination of clinical evaluation, imaging studies, and histopathological analysis. Patients often present with systemic symptoms such as fever, night sweats, and weight loss, alongside lymphadenopathy or extranodal involvement. Biopsy of affected tissues is crucial for confirming the diagnosis, revealing a proliferation of atypical B-cells with characteristic cytological features and genetic abnormalities, such as MYC or BCL2 rearrangements, which are indicative of high-grade transformation. Flow cytometry and molecular genetic testing further refine the diagnosis, distinguishing DHGB-DL from other aggressive lymphomas and guiding treatment decisions. Early and accurate diagnosis is pivotal for initiating timely and appropriate therapy, which can significantly impact patient outcomes.
Management
The management of DHGB-DL is multifaceted, encompassing aggressive chemotherapy regimens, often in the context of clinical trials, and supportive care measures. Despite the availability of healthcare proxies and do-not-resuscitate (DNR) orders in a majority of patients, engagement in advance care planning (ACP) remains suboptimal. According to a study [PMID:31633432], only 34.6% of patients have completed living wills, and 44.4% have discussed their care preferences with others, indicating a significant gap in comprehensive patient-centered care planning. This suboptimal engagement can lead to misalignment between patient wishes and clinical interventions, potentially affecting treatment adherence and quality of life. In clinical practice, it is essential to proactively address these gaps by integrating ACP discussions early in the patient's journey, ensuring that patients and their families are well-informed about prognosis and treatment goals.
Treatment strategies for DHGB-DL typically include intensive chemotherapy regimens such as dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) or hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, and dexamethasone) alternating with high-dose methotrexate. In some cases, autologous stem cell transplantation may be considered for eligible patients to consolidate remission. Targeted therapies and immunotherapies, such as rituximab or newer agents targeting specific genetic alterations, are increasingly integrated into treatment protocols to enhance efficacy. However, the aggressive nature of DHGB-DL necessitates a multidisciplinary approach, combining hematology-oncology expertise with palliative care to manage symptoms and side effects effectively, thereby improving patient comfort and functional status throughout treatment.
Prognosis & Follow-up
The prognosis for patients with DHGB-DL remains guarded despite advances in treatment. Studies indicate that while patients frequently engage in discussions about curability, prognosis, and treatment goals with their medical teams [PMID:31633432], a significant proportion underestimates the severity of their condition. Only 29.6% recognized being terminally ill, and 22.2% acknowledged having incurable disease, highlighting a critical need for clearer communication regarding prognosis. This misperception can lead to unrealistic expectations and suboptimal decision-making regarding treatment options and end-of-life care. Regular follow-up is essential to monitor disease progression, manage treatment-related toxicities, and reassess treatment efficacy. Follow-up protocols typically include periodic imaging studies, blood tests to assess tumor markers, and clinical evaluations to detect early signs of relapse or complications.
Supportive care plays a crucial role in managing symptoms and improving quality of life. This includes addressing pain management, infection prophylaxis, and psychological support to cope with the emotional burden of the diagnosis. Given the aggressive nature of DHGB-DL, ongoing communication about prognosis and the potential for disease progression is vital. Healthcare providers should facilitate open dialogues about realistic outcomes and the importance of advance directives to ensure that patients' wishes are respected as the disease evolves.
Key Recommendations
Based on the evidence presented [PMID:31633432], several key recommendations emerge to enhance patient care and engagement in DHGB-DL management:
These recommendations aim to bridge the gap identified in patient engagement and communication, ultimately improving patient outcomes and quality of life in the context of managing DHGB-DL.
References
1 Trevino KM, Rutherford SC, Marte C, Ouyang DJ, Martin P, Prigerson HG et al.. Illness Understanding and Advance Care Planning in Patients with Advanced Lymphoma. Journal of palliative medicine 2020. link
1 papers cited of 3 indexed.